Prognostic value of pleural fluid pH in malignant epithelial mesothelioma after talc poudrage

Respiration

Volumn 73, Issue 3, 2006, Pages 334-339

  Aelony, Yossef ^a   Yao, Janis F ^a   King, Handel R ^a  

^a KAISER PERMANENTE   (United States)

Author keywords

Malignant pleural effusion; Pleurodesis; Thoracoscopy

Indexed keywords

TALC;

CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; LUNG RESECTION; MALE; MALIGNANT MESOTHELIOMA; NON INVASIVE MEASUREMENT; PH; PLEURA FLUID; PLEURA FLUID PH; PLEURA MESOTHELIOMA; PLEURODESIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; STATISTICAL PARAMETERS; THORACOSCOPY;

FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; MESOTHELIOMA; PLEURAL EFFUSION, MALIGNANT; PROGNOSIS; RETROSPECTIVE STUDIES; ROC CURVE; TALC; THORACOSCOPY;

EID: 33646580343     PISSN: 00257931     EISSN: None     Source Type: Journal    
DOI: 10.1159/000092085     Document Type: Review

References (20)

1. Sahn SA, Good JT Jr: Pleural fluid pH in malignant effusions. Diagnostic, prognostic, and therapeutic implications. Ann Intern Med 1988;108:345-349.
2. Sahn SA, Heffner JE: Pleural fluid analysis; in Light RW, Lee YC (eds): Textbook of Pleural Diseases. London, Arnold, 2003, pp 191-209.
3. Rodriguez-Panadero F, Lopez Mejias J: Low glucose and pH levels in malignant pleural effusions. Diagnostic significance and prognostic value in respect to pleurodesis. Am Rev Respir Dis 1989;139:663-667.
4. Gottehrer A, Taryle DA, Reed CE, Sahn SA: Pleural fluid analysis in malignant mesothelioma. Prognostic implications. Chest 1991;100:1003-1006.
5. Aelony Y, Yao J: Malignant pleural mesothelioma: a case series with prolonged survival averaging 22.4 months after treatment with thoracoscopic talc poudrage pleurodesis (abstract). Am J Respir Crit Care Med 1999;159:A212.
6. Aelony Y, King R, Boutin C: Thoracoscopic talc poudrage pleurodesis for chronic recurrent pleural effusions. Ann Intern Med 1991;115:778-782.
7. Aelony Y, King RR, Boutin C: Thoracoscopic talc poudrage in malignant pleural effusions: effective pleurodesis despite low pleural pH. Chest 1998;113:1007-1012.
8. Sugarbaker DJ, Flores RM, Jaklitsch MT, Richards WG, Strauss GM, Corson JM, et al: Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 1999;117:54-63; discussion 63-65.
9. Aelony Y: Treatment of mesotheliomatous pleural effusion: experimental therapy versus thoracoscopic talc poudrage? Pro: talc poudrage therapy. J Bronchol 2001;8:54-59.
10. Astoul P: Malignant mesothelioma; in Light RW, Lee YC (eds): Textbook of Pleural Diseases. London, Arnold, 2003, pp 435-444.
11. Curran D, Sahmoud T, Therass P, van Meerbeeck J, Postmus PE, Giaccone G: Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer Experience. J Clin Oncol 1998;16:145-152.
12. Herndon JE, Green MR, Chahinian AP, Corson JM, Suzuki Y, Vogelzang NJ: Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 1998;113:723-731.
13. Rusch VW: A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. Chest 1995;108:1122-1128.
14. Pass HI: Pleural mesothelioma in 2002: going somewhere very slowly. J Thorac Cardiovasc Surg 2002;124:1074-1077.
15. Hillerdal G: Staging and evaluating responses in malignant pleural mesothelioma. Lung Cancer 2004;43:75-76.
16. Edwards JG, Abrams KR, Leverment JN, Spyt TJ, Waller DA, O'Byrne KJ: Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems. Thorax 2000;55:731-735.
17. 18F-FDG uptake in malignant pleural mesothelioma. Thorax 2003;58:1077-1082.
18. Edwards JG, Swinson DE, Jones JL, Muller S, Waller DA, O'Byrne KJ: Tumor necrosis correlates with angiogenesis and is a predictor of poor prognosis in malignant mesothelioma. Chest 2003;124:1916-1923.
19. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al: Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636-2644.
20. Muers MF, Rudd RM, O'Brien ME, Qian W, Hodson A, Parmar MK, et al: British Thoracic Society Mesothelioma Group. BTS randomised feasibility study of active symptom control with or without chemotherapy in malignant pleural mesothelioma: ISRCTN 54469112. Thorax 2004;59:144-148.